A total of 136, 21, and 82 patients received at least one open-label dose in studies 301, 301EXT, and 302EXT, respectively.
Uuringutes 301, 301EXT ja 302EXT manustati kokku vastavalt 136, 21 ja 82 patsiendile vähemalt üks avatud annus.